Rallybio Corp Company Insiders
RLYB Stock | USD 0.33 0 0.33% |
Rallybio Corp employs about 24 people. The company is managed by 6 executives with a total tenure of roughly 56 years, averaging almost 9.0 years of service per executive, having 4.0 employees per reported executive. Analysis of Rallybio Corp's management performance can provide insight into the company performance.
Insider Sentiment 50
Impartial
Selling | Buying |
Latest Trades
2023-03-14 | Jonathan I Lieber | Acquired 5000 @ 5.21 | View | ||
2023-03-07 | Kush Parmar | Disposed 100000 @ 8.2 | View |
Monitoring Rallybio Corp's insider sentiment can offer insights into its future performance, as insiders often have access to more information about their company's operations, financial health, and upcoming initiatives than the general public. However, it's essential to note that insider trading is regulated by securities laws, and insiders are required to disclose their trades publicly to ensure transparency and prevent unfair advantages based on non-public information.
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Rallybio Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in manufacturing. Rallybio Corp Management Team Effectiveness
The company has return on total asset (ROA) of (0.4002) % which means that it has lost $0.4002 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6728) %, meaning that it created substantial loss on money invested by shareholders. Rallybio Corp's management efficiency ratios could be used to measure how well Rallybio Corp manages its routine affairs as well as how well it operates its assets and liabilities. At present, Rallybio Corp's Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 204.5 M, whereas Non Current Assets Total are forecasted to decline to about 253.7 K.As of July 2, 2025, Common Stock Shares Outstanding is expected to decline to about 38.9 M. In addition to that, Net Loss is expected to decline to about (63 M)
Rallybio Corp Workforce Comparison
Rallybio Corp is currently regarded as top stock in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 147,492. Rallybio Corp adds roughly 24.0 in number of employees claiming only tiny portion of equities under Health Care industry.
Rallybio Corp Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Rallybio Corp insiders, such as employees or executives, is commonly permitted as long as it does not rely on Rallybio Corp's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Rallybio Corp insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Hunt Ronald over a month ago Acquisition by Hunt Ronald of 13440 shares of Rallybio Corp at 12.75 subject to Rule 16b-3 | ||
Hopfner Robert Lorne over a month ago Acquisition by Hopfner Robert Lorne of 28500 shares of Rallybio Corp at 0.3 subject to Rule 16b-3 | ||
Martin MacKay over a month ago Acquisition by Martin MacKay of 28500 shares of Rallybio Corp at 0.3 subject to Rule 16b-3 | ||
Martin MacKay over two months ago Acquisition by Martin MacKay of 436517 shares of Rallybio Corp subject to Rule 16b-3 | ||
Martin MacKay over two months ago Acquisition by Martin MacKay of 216000 shares of Rallybio Corp at 1.86 subject to Rule 16b-3 | ||
Ryder Steven over three months ago Acquisition by Ryder Steven of 62000 shares of Rallybio Corp at 15.04 subject to Rule 16b-3 | ||
Ryder Steven over three months ago Acquisition by Ryder Steven of 180000 shares of Rallybio Corp at 0.76 subject to Rule 16b-3 | ||
Liu Hui over six months ago Acquisition by Liu Hui of 67857 shares of Rallybio Corp at 0.95 subject to Rule 16b-3 |
Rallybio Corp Notable Stakeholders
A Rallybio Corp stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Rallybio Corp often face trade-offs trying to please all of them. Rallybio Corp's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Rallybio Corp's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Martin MacKay | CoFounder Chairman | Profile | |
MD MB | President, CoFounder | Profile | |
Jonathan MBA | CFO Treasurer | Profile | |
Ami Bavishi | Head Communications | Profile | |
Jeffrey CPA | CFO CoFounder | Profile | |
MD FACP | Chief Officer | Profile |
About Rallybio Corp Management Performance
The success or failure of an entity such as Rallybio Corp often depends on how effective the management is. Rallybio Corp management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Rallybio management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Rallybio management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Rallybio Corporation, a clinical-stage biotechnology company, engages in discovering, developing, manufacturing, and delivering therapies that enhance the lives of patients suffering from severe and rare diseases. Rallybio Corporation was founded in 2018 and is headquartered in New Haven, Connecticut. Rallybio Corporaton operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 45 people.
Please note, the presentation of Rallybio Corp's financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Rallybio Corp's management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Rallybio Corp's management manipulating its earnings.
Rallybio Corp Workforce Analysis
Traditionally, organizations such as Rallybio Corp use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Rallybio Corp within its industry.Rallybio Corp Manpower Efficiency
Return on Rallybio Corp Manpower
Revenue Per Employee | 26.5K | |
Revenue Per Executive | 106K | |
Net Loss Per Employee | 2.4M | |
Net Loss Per Executive | 9.6M | |
Working Capital Per Employee | 2.6M | |
Working Capital Per Executive | 10.3M |
Complementary Tools for Rallybio Stock analysis
When running Rallybio Corp's price analysis, check to measure Rallybio Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Rallybio Corp is operating at the current time. Most of Rallybio Corp's value examination focuses on studying past and present price action to predict the probability of Rallybio Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Rallybio Corp's price. Additionally, you may evaluate how the addition of Rallybio Corp to your portfolios can decrease your overall portfolio volatility.
Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
Stocks Directory Find actively traded stocks across global markets | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
Transaction History View history of all your transactions and understand their impact on performance | |
Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
Idea Analyzer Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas |